Tonix Announces CMO Selection for Tonmya Fibromyalgia Drug Launch

Wednesday, 20 March 2024, 17:02

Tonix (TNXP) has made strategic moves by appointing two CMOs to supply its non-opioid pain reliever, Tonmya, for fibromyalgia patients in the US. The decision signals the progress towards the anticipated launch of the innovative drug, offering a new treatment option for individuals suffering from fibromyalgia. Tonix's choice of CMOs underscores the company's commitment to bringing novel, effective therapies to market and addressing unmet medical needs.

https://store.livarava.com/aa5ab0b4-e6dc-11ee-968c-5254a2021b2b.jpe — Tonix Announces CMO Selection for Tonmya Fibromyalgia Drug Launch

Tonix's Latest Development in Fibromyalgia Treatment

Tonix (TNXP) has taken a significant step towards launching a new non-opioid pain reliever, Tonmya, for individuals with fibromyalgia. The company has recently announced the selection of two Contract Manufacturing Organizations (CMOs) as suppliers for the potential US release of the drug.

Strategic Move for Market Entry

This decision solidifies Tonix's position in the healthcare sector and highlights its dedication to providing innovative solutions to patients. Tonmya's introduction could address the pressing need for alternative treatments for fibromyalgia, offering hope to those affected by the condition.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.